https://orcid.org/0000-0003-3132-1870
References
- Chu CY, Choi J, Eaby-Sandy B, et al. Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer. Oncologist. 2018;23(8):891–899.
- Lertpichitkul P, Wititsuwannakul J, Asawanonda P, et al. Osimertinib-associated ashy dermatosis-like hyperpigmentation. JAAD Case Rep. 2020;6(2):86–88.
- Fan M, Mo T, Shen L, et al. Osimertinib-induced severe interstitial lung disease: a case report. Thorac Cancer. 2019;10(7):1657–1660.
- Yi L, Fan J, Qian R, et al. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: a Meta-analysis. Int J Cancer. 2019;145(1):284–294.
- Murtuza A, Bulbul A, Shen JP, et al. Novel Third-Generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79(4):689–698.
- Sato I, Mizuno H, Kataoka N, et al. Osimertinib-Associated toxic epidermal necrolysis in a lung cancer patient harboring an EGFR Mutation-A case report and a review of the literature. Medicina (Kaunas). 2020;56(8):403.
- Hamada K, Oishi K, Okita T, et al. Cutaneous vasculitis induced by osimertinib. J Thorac Oncol. 2019;14(12):2188–2189.
- Ferro A, Filoni A, Pavan A, et al. Subacute cutaneous lupus Erythematosus-Like eruption induced by EGFR -Tyrosine kinase inhibitor in EGFR-Mutated non-small cell lung cancer: a case report. Front Med. 2021;8:570921.
- Daze RP, Dinkins J, Mahoney MH. Osimertinib and ramucirumab induced pyogenic granulomas: a possible synergistic effect of dual oncologic therapy. Cureus. 2021;13(5):e15076.
- Kumarasinghe SPW, Pandya A, Chandran V, et al. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and riehl's melanosis. Int J Dermatol. 2019;58(3):263–272.
- Leung N, Oliveira M, Selim MA, et al. Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol. 2018;4(4):216–222.
- Robles-Mendez JC, Rizo-Frias P, Herz-Ruelas ME, et al. Lichen planus pigmentosus and its variants: review and update. Int J Dermatol. 2018;57(5):505–514.
- Baranda L, Torres-Alvarez B, Cortes-Franco R, et al. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). the effect of clofazimine therapy. Arch Dermatol. 1997;133(3):325–329.
- Pinkus H. Lichenoid tissue reactions. A speculative review of the clinical spectrum of epidermal basal cell damage with special reference to erythema dyschromicum perstans. Arch Dermatol. 1973;107(6):840–846.